Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Bik To

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Blood|August 12, 2011
How I treat patients who mobilize hematopoietic stem cells poorlyL Bik To, Jean-Pierre Levesque, Kirsten E Herbert
Stem Cells (Dayton, Ohio)|June 23, 2009
Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient miceSmita D Hiwase, Pamela G Dyson, L Bik To, et al.
Methods in Molecular Medicine|June 22, 2005
An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factorsAndrew C W Zannettino, Amanda N Farrugia, L Bik To, et al.
Blood|June 16, 2005
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLDeborah White, Verity Saunders, A Bruce Lyons, et al.
Leukemia Research|October 14, 2011
The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemiaSonya M Diakiw, Chung H Kok, L Bik To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myelomaSally K Martin, Andrea L Dewar, Amanda N Farrugia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaDeborah White, Verity Saunders, Andrew Grigg, et al.
Blood|February 2, 2006
Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar, Amanda N Farrugia, Mark R Condina, et al.
Haematologica|November 5, 2020
Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>Mara N Zeissig, Duncan R Hewett, Vasilios Panagopoulos, et al.
Cancer Research|September 23, 2003
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivoAmanda N Farrugia, Gerald J Atkins, L Bik To, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Blood|August 12, 2011
How I treat patients who mobilize hematopoietic stem cells poorlyL Bik To, Jean-Pierre Levesque, Kirsten E Herbert
Stem Cells (Dayton, Ohio)|June 23, 2009
Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient miceSmita D Hiwase, Pamela G Dyson, L Bik To, et al.
Methods in Molecular Medicine|June 22, 2005
An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factorsAndrew C W Zannettino, Amanda N Farrugia, L Bik To, et al.
Blood|June 16, 2005
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CMLDeborah White, Verity Saunders, A Bruce Lyons, et al.
Leukemia Research|October 14, 2011
The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemiaSonya M Diakiw, Chung H Kok, L Bik To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Tumor angiogenesis is associated with plasma levels of stromal-derived factor-1alpha in patients with multiple myelomaSally K Martin, Andrea L Dewar, Amanda N Farrugia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaDeborah White, Verity Saunders, Andrew Grigg, et al.
Blood|February 2, 2006
Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar, Amanda N Farrugia, Mark R Condina, et al.
Haematologica|November 5, 2020
Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells <i>in vivo</i>Mara N Zeissig, Duncan R Hewett, Vasilios Panagopoulos, et al.
Cancer Research|September 23, 2003
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivoAmanda N Farrugia, Gerald J Atkins, L Bik To, et al.
Pageof 3